Dupixent
(Dupilumab)ApprovedMonoclonal antibody
Dupilumab is used to treat moderate to severe eczema, asthma, and chronic rhinosinusitis by reducing inflammation and helping the immune system stop overreacting to allergens and irritants.[2] Dupixent is currently approved and in use across 34 indications[4].[1]
Dupixent is one of 461 monoclonal antibody programs targeting Eosinophilic Esophagitis. It is currently in Approved.
34
Indications
225
Total Trials
69
Active Trials
460
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 33 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Approved
Adenocard
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis60 trials
Show 57 more trials
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT03389893·72 enrolled
Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood
Unknown status·NNational Medical Research Center for Children's Health, Russian Federation·Phase 4·NCT04895423·160 enrolled
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT05436535·433 enrolled
Asthma27 trials
Show 24 more trials
Investigating Dupilumab's Effect in Asthma by Genotype
Active, not recruiting·—·Phase 4·NCT03694158·150 enrolled
Similarities and Differences of Biological Therapies for Severe Asthma.
Unknown status·—··NCT04665141·600 enrolled
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05347771·240 enrolled
Eosinophilic Esophagitis9 trials
Show 6 more trials
Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
Completed·—·Phase 4·NCT05247866·21 enrolled
Prurigo Nodularis5 trials
Chronic Rhinosinusitis4 trials
Show 1 more trial
Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps
Not yet recruiting·—·Phase 4·NCT06556264·60 enrolled
66 more indications
Allergy3 trials
Nasal polyposis3 trials
Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis
Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 4·NCT04869436·27 enrolled
Bullous Pemphigoid3 trials
Chronic Spontaneous Urticaria3 trials
Nasal Polyps3 trials
Chronic Rhinosinusitis With Nasal Polyps2 trials
CRSwNP2 trials
Inflammation2 trials
Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion
Unknown status·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau··NCT05787678·30 enrolled
Pruritus2 trials
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
Recruiting·—·Phase 2·NCT06226610·46 enrolled
Efficacy and Safety2 trials
Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT06465732·220 enrolled
Atopic Eczema2 trials
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
Recruiting·—·Phase 4·NCT06004986·216 enrolled
Chronic Obstructive Pulmonary Disease2 trials
Tics2 trials
Treatment2 trials
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
Completed·—·Phase 4·NCT04358224·12 enrolled
Keloid2 trials
Lichen Simplex Chronicus2 trials
Sinusitis1 trial
Dermatitis1 trial
Adolescent1 trial
Allergic Bronchopulmonary Aspergillosis1 trial
Effectiveness1 trial
Breast Cancer1 trial
Chronic Rhinosinusitis Without Nasal Polyps1 trial
Insulin resistance1 trial
Sleep Apnea1 trial
Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis
Terminated·—·Phase 1·NCT03675022·9 enrolled
Moderate to Severe COPD1 trial
Scleroderma1 trial
Prevention1 trial
Dupilumab for Prevention of Recurrence of CRSwNP After ESS
Completed·—·Phase 4·NCT04596189·30 enrolled
Pregnancy1 trial
Biosimilarity1 trial
Eosinophilic Gastritis1 trial
Dupilumab in Eosinophilic Gastritis
Completed·—·Phase 2·NCT03678545·41 enrolled
Ichthyosis1 trial
Prostate Cancer1 trial
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03886493·7 enrolled
Netherton syndrome1 trial
Colonization1 trial
Cold Urticaria1 trial
Single Dose1 trial
Urticaria1 trial
Cholinergic Urticaria - Efficacy of Dupilumab
Completed·—·Phase 2·NCT03749148·48 enrolled
Keratoconjunctivitis1 trial
Contact Dermatitis1 trial
Hypersensitivity1 trial
Allergic1 trial
Type 2 Inflammatory Disorders1 trial
Metastatic Non Small Cell Lung Cancer1 trial
Eosinophilic Esophagitis (EoE)1 trial
Hypereosinophilic syndrome1 trial
Chronic Spontaneous Urticaria (CSU)1 trial
Non-Small Cell Lung Cancer1 trial
Unspecified9 trials
Show 6 more trials
Dupilumab Therapy for EGIDs
Recruiting·—··NCT07257835·20 enrolled
Regulatory
FDA Approval Timeline[5]
Mar 28, 2017
Dupixent
BLA 761055
Mar 28, 2017
DUPIXENT
BLA BLA761055
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Dupixent drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Dupilumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]